TRAUMATIC BRAIN INJURY THERAPEUTICS MARKET ANALYSIS

Traumatic Brain Injury Therapeutics MarketSize and Trends

Traumatic Brain Injury Therapeutics Market: Drivers

Increasing number of pipeline studies to develop new treatments for TBI is expected to boost the traumatic brain injury therapeutics market growth during the forecast period. For instance, in August 2017, Australian and New Zealand Intensive Care Research Center, in collaboration with Monash University, initiated a clinical trial to determine long-term effects of erythropoietin in patients with moderate to severe TBI. Erythropoietin is a hormone produced by the kidneys and plays crucial role in the production of red blood cells (RBCs). The study is expected to be completed by May 2019.

Similarly, in June 2016, Vasopharm GmbH, in collaboration with ICON plc, started phase 3 clinical study for VAS203 (Ronopterin) to evaluate its efficacy in patients with moderate and severe TBI (NOSTRA-III). The study is expected to be completed by June 2019.

Traumatic Brain Injury Therapeutics Market: Taxonomy

By Treatment Type

• Drugs
  • Antianxiety
  • Anticoagulants
  • Antidepressants
  • Muscles relaxants
  • Stimulants
  • Other Medications

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa